PRDX2 silencing resulted in increased sensitivity of osteosarcoma cells to chemotherapy (methotrexate, doxorubicin and cisplatin) and a decrease in cell proliferation, invasion and migration in functional assays. The gene discussed is PRDX2; the disease is osteosarcoma.